Annexon (NASDAQ:ANNX) Stock Falls 4.6% – Here’s Why

Annexon, Inc. (NASDAQ:ANNX) shares fell 4.6% during mid-day trading on Tuesday. The company traded as low as $3.83 and last traded at $3.8250. Approximately 1,864,518 shares were traded during mid-day trading, a decline of 38% from the average session volume of 2,995,185 shares. The stock had previously closed at $4.01.

Key Annexon News

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook, projecting EPS of $0.58 in fiscal 2029 and $1.36 in fiscal 2030, compared with previous estimates of $0.03 and $0.45, respectively. The firm also narrowed its projected 2028 loss to $0.16 per share from $0.39 and its 2027 loss to $0.69 from $0.74.
• Positive Sentiment: The unchanged Buy rating and $14 price objective imply substantial upside from current levels, reflecting expectations that Annexon’s development programs could eventually generate meaningful earnings.
• Neutral Sentiment: HC Wainwright forecasts continued losses through 2028, including EPS of approximately negative $0.20 per quarter during 2027. The company remains a development-stage biotechnology business, so the long-term projections are dependent on clinical and commercial execution.
• Negative Sentiment: The analyst reduced its estimates for third-quarter 2026 EPS to a loss of $0.28 from $0.27, fourth-quarter 2026 EPS to a loss of $0.24 from $0.22, and full-year 2026 EPS to a loss of $1.03 from $0.99. These revisions indicate somewhat higher expected near-term spending or losses.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ANNX. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Annexon in a report on Monday, July 20th. Citizens Jmp upgraded shares of Annexon from an “underperform” rating to a “market perform” rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. raised their price objective on shares of Annexon from $14.00 to $15.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 30th. Wall Street Zen lowered shares of Annexon from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Monday, July 13th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $15.29.

Annexon Price Performance

The firm has a 50 day moving average of $4.39 and a 200-day moving average of $5.12. The stock has a market capitalization of $731.78 million, a P/E ratio of -3.33 and a beta of 1.32.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). As a group, equities analysts expect that Annexon, Inc. will post -1.05 earnings per share for the current year.

Insider Activity at Annexon

In other news, CEO Douglas Love bought 26,065 shares of the business’s stock in a transaction that occurred on Thursday, September 24th. The stock was acquired at an average cost of $3.83 per share, for a total transaction of $99,828.95. Following the completion of the purchase, the chief executive officer owned 390,476 shares of the company’s stock, valued at $1,495,523.08. This trade represents a 7.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.31% of the company’s stock.

Institutional Investors Weigh In On Annexon

Institutional investors have recently bought and sold shares of the business. Abel Hall LLC bought a new stake in Annexon in the 1st quarter valued at $61,000. Sowell Financial Services LLC bought a new position in shares of Annexon during the 3rd quarter worth about $57,000. Integrated Wealth Concepts LLC lifted its holdings in shares of Annexon by 32.3% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 13,537 shares of the company’s stock worth $77,000 after acquiring an additional 3,305 shares during the period. Forefront Analytics LLC bought a new position in shares of Annexon during the 2nd quarter worth about $81,000. Finally, Pictet Asset Management Holding SA acquired a new stake in shares of Annexon during the 1st quarter valued at about $93,000.

About Annexon

Annexon, Inc (NASDAQ: ANNX) is a clinical-stage biotechnology company developing therapies for diseases associated with abnormal activation of the classical complement pathway. The company’s approach is designed to selectively inhibit complement activity while preserving the immune system’s ability to perform essential functions.

Annexon’s pipeline has included ANX005, a monoclonal antibody targeting C1q, the initiating protein of the classical complement pathway. The company has evaluated ANX005 in immune-mediated and neuroinflammatory disorders, including Guillain-Barré syndrome.